Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
May 07 2008 - 8:30AM
PR Newswire (US)
WESTFORD, Mass., May 7 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ:CYNO), a leading developer and manufacturer of a broad
array of light-based aesthetic treatment systems, today announced
that it has received market approval from the Korea Food & Drug
Administration (KFDA) for its flagship Accolade(TM) workstation for
the removal of pigmented lesions. Introduced in the first quarter
of 2008, the Accolade is the third Cynosure flagship product
approved for marketing in South Korea, following the Elite(TM)
Aesthetic Workstation for laser hair removal and the Cynergy(TM)
Workstation with MultiPlex(TM) Technology for the treatment of
dermatological vascular conditions. All three workstations are
being distributed in South Korea through Seoul-based OrientMG Ltd.
"As one of the world's major aesthetic markets, we believe South
Korea represents a valuable growth opportunity for our products,
and we are excited about the receipt of KFDA approval for our
newest flagship product," said Cynosure President and Chief
Executive Officer Michael Davin. "Due to the prevalence of dermal
melanoses among Asian populations, South Korea is a primary target
market for Accolade. We also are pursuing regulatory approval in
other Asia Pacific countries, including China." Accolade is a
high-powered 755 nm, Q-switched Alexandrite laser for the removal
of pigmented lesions. The unique combination of various spot sizes
and the laser's high repetition rates allow for rapid treatment.
"With its power and precision, Accolade is well-suited for treating
the full spectrum of benign pigmented lesions including Nevus of
Ota, solar lentigenes, freckles and sun-damaged pigmentation," said
Dr. Joon-hong Park of the Maymorning Clinic in Sungnam City,
Kyunggi-Do, South Korea. "The accuracy of the aiming beam makes the
Accolade easy to handle- treatment is delivered with specificity,
minimizing side effects to the surrounding tissue and maximizing
patient comfort." About Cynosure, Inc. Cynosure, Inc. develops and
markets aesthetic treatment systems that are used by physicians and
other practitioners to perform non-invasive and minimally invasive
procedures to remove hair, treat vascular lesions, rejuvenate skin
through the treatment of shallow vascular and pigmented lesions,
laser lipolysis and temporarily reduce the appearance of cellulite.
Cynosure's products include a broad range of laser and other
light-based energy sources, including Alexandrite, pulsed dye,
Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure
was founded in 1991. For corporate or product information, contact
Cynosure at 800-886-2966, or visit http://www.cynosure.com/. Safe
Harbor Any statements in this press release about future
expectations, plans and prospects for Cynosure, Inc., including
statements about the company's expectations and future financial
performance, as well as other statements containing the words
"believes," "anticipates," "plans," "expects," "will" and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including Cynosure's reliance on sole source suppliers,
the inability to accurately predict the timing or outcome of
regulatory decisions, changes in consumer preferences, competition
in the aesthetic laser industry, economic, market, technological
and other factors discussed in Cynosure's most recent Annual Report
on Form 10-K, which is filed with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent Cynosure's views as of the date of
this press release. Cynosure anticipates that subsequent events and
developments will cause its views to change. However, while
Cynosure may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. These forward-looking statements should not be relied
upon as representing Cynosure's views as of any date subsequent to
the date of this press release. Contact: Scott Solomon Vice
President Sharon Merrill Associates, Inc. 617.542.5300 DATASOURCE:
Cynosure, Inc. CONTACT: Scott Solomon, Vice President of Sharon
Merrill Associates, Inc., +1-617-542-5300, Web site:
http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024